PEA-15 (phosphoprotein enriched in astrocytes 15 kDa) is a death effector domain-containing protein, which is involved in the regulation of apoptotic cell death. Since PEA-15 is highly expressed in cells of glial origin, we studied the role of PEA-15 in human malignant brain tumors. Immunohistochemical analysis of PEA-15 expression shows strong immunoreactivity in astrocytomas and glioblastomas. Phosphorylation of PEA-15 at Ser 116 is found in vivo in perinecrotic areas in glioblastomas and in vitro after glucose deprivation of glioblastoma cells. Overexpression of PEA-15 induces a marked resistance against glucose deprivation-induced apoptosis, whereas small interfering RNA (siRNA)-mediated downregulation of endogenous PEA-15 results in the sensitization to glucose withdrawal-mediated cell death. This antiapoptotic activity of PEA-15 under low glucose conditions depends on its phosphorylation at Ser 116 . Moreover, siRNA-mediated knockdown of PEA-15 abolishes the tumorigenicity of U87MG glioblastoma cells in vivo. PEA-15 regulates the level of phosphorylated extracellular-regulated kinase (ERK)1/2 in glioblastoma cells and the PEA-15-dependent protection from glucose deprivation-induced cell death requires ERK1/2 signaling. PEA-15 transcriptionally upregulates the Glucose Transporter 3, which is abrogated by the inhibition of ERK1/2 phosphorylation. Taken together, our findings suggest that Ser Introduction PEA-15/PED (phosphoprotein enriched in astrocytes 15 kDa/phosphoprotein enriched in diabetes) is a multifunctional protein that has been described to be highly expressed in astrocytes (Araujo et al., 1993; Danziger et al., 1995) . The C-terminal part of the protein contains two serine residues (Ser 104 and Ser
116
), which can be phosphorylated by protein kinase C (PKC), calcium/ calmodulin-dependent protein kinase II (CaMKII) and Akt (Kubes et al., 1998; Trencia et al., 2003) . Since PEA-15 contains a classical death effector domain (DED) in the N-terminal segment, many reports have concentrated on the PEA-15-dependent modulation of death receptor-mediated apoptosis. PEA-15 was described as a component of the death-inducing signaling complex (DISC) and it inhibits CD95-and TRAIL receptor-mediated apoptosis, presumably by binding to Fas-associated death domain and/or caspase 8 (Condorelli et al., 1999; Estelles et al., 1999; Kitsberg et al., 1999; Hao et al., 2001) . The DED-mediated antiapoptotic activity of PEA-15 depends on the phosphorylation status, since the Ser 116 -or double-phosphorylated forms are preferentially recruited to the DISC (Xiao et al., 2002; Renganathan et al., 2005; Song et al., 2006) . Apart from its apoptosis-related effects, PEA-15 is a potent modulator of the mitogen-activated protein (MAP) kinase signaling cascades. PEA-15 binds to and sequesters extracellular-regulated kinase (ERK)1/2 in the cytoplasm, thereby preventing its nuclear translocation and the subsequent phosphorylation of nuclear targets (Ramos et al., 2000; Formstecher et al., 2001; Condorelli et al., 2002; Whitehurst et al., 2004; Krueger et al., 2005) . The regulation of MAP/ERK-dependent pathways by PEA-15 might also play a role in other biological functions of this protein, which are especially important in cancer cells, such as integrin activation (Ramos et al., 1998; Chou et al., 2003) , chemoresistance (Stassi et al., 2005) and migration (Renault-Mihara et al., 2006) .
On the other hand, PEA-15 was initially described as a diabetes mellitus-related protein, hence the alternative designation PED (Condorelli et al., 1998) . PEA-15/PED plays an important role in glucose metabolism and its overexpression contributes to the development of diabetes mellitus (Vigliotta et al., 2004) . However, the question whether PEA-15 plays a role in glucose metabolism in cancer cells has not been addressed so far. Glioblastoma multiforme, the most malignant of all brain tumors, is known to heavily depend on glucose consumption and was therefore chosen as a model for our studies. Although PEA-15 was originally described to be predominantly expressed in astrocytes as long as 13 years ago, only little is known about the expression of this protein in astrocytic brain tumors.
Here (Figures 1a and b) . On the subcellular level, PEA-15 immunoreactivity was mainly seen in the cytoplasm in a diffuse pattern (Figure 1b ). In the normal brain tissue, PEA-15 expression was weak or absent, with its highest expression in reactive astrocytes ( Figures  1a and b) . The choroideal plexus and endothelial cells were negative for PEA-15 staining. Immunohistochemical analysis of adenocarcinoma revealed a substantially lower expression level of PEA-15 in carcinoma cells than in astrocytoma and glioblastoma cells (data not shown).
Since the cellular functions of PEA-15 depend on its phosphorylation status, we performed additional immunohistochemical studies with an antibody specific for the Ser 116 -phosphorylated form of PEA-15. In general, the expression level of Ser 116 -phospho-PEA-15 was lower and confined to specific intratumoral areas. The strongest immunoreactivity was seen in perinecrotic areas in glioblastomas (Figure 1c) . In 10 analysed glioblastoma samples, 64% of the necrotic areas exhibited perinecrotic immunoreactivity for Ser 116 -phospho-PEA-15. Necrotic areas are a typical histomorphological hallmark of glioblastomas and are characterized by a lack of oxygen and nutrients. Next, we examined the PEA-15 expression in freshly obtained glioblastoma cell cultures (passages o5) by western blot analysis. All of the samples tested exhibited high total PEA-15 and Ser
-phospho-PEA-15 expression levels (Figure 1d ). The expression level of Ser
-phospho-PEA-15 was substantially higher than in the two long-term glioma cell lines, U87MG and U251MG.
Glucose withdrawal results in phosphorylation of PEA-15 Given the known role of PEA-15 in glucose metabolism and the predominant expression of Ser 116 -phospho-PEA-15 in perinecrotic areas in glioblastomas, we wondered whether the lack of nutrients, such as glucose, induces phosphorylation of PEA-15. To test this hypothesis, we exposed glioma cells to a culture medium with reduced levels of glucose (25 mM) and determined the resulting phosphorylation of PEA-15 by western blot analysis. Glioma cell cultures showed increased Ser 116 phosphorylation of PEA-15 upon glucose deprivation ( Figure 2a ). The extent of the phosphorylation correlated inversely with the concentration of glucose in the culture medium, since Ser 116 phosphorylation increased with decreasing glucose levels ( Figure 2b ). The phosphorylation of Ser 116 was also observed under hypoxic conditions with or without concomitant glucose withdrawal (Figure 2c ). Since several protein kinases can phosphorylate PEA-15 at the two serine residues 104 and 116, we treated the glioma cells with protein kinase inhibitors to specify the protein kinase(s) responsible for Ser 116 phosphorylation in response to glucose withdrawal. Interestingly, Ser 116 phosphorylation was completely blocked by BIS-VIII, a PKC inhibitor, and partially blocked by KN-93, a CAMKII inhibitor. An Akt inhibitor (hydroxymethyl-chiro-inositol 2-(R)-2-Omethyl-3-O-octadecylcarbonate (HMIMO)) did not 
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, whereas under conditions of glucose deprivation, this percentage increases to approx. 55%.
PEA-15 induces cellular resistance against glucose deprivation-induced apoptosis Given the high PEA-15 expression levels in malignant brain tumors, we investigated the functional consequences of elevated PEA-15 expression in glioblastoma cells. We generated several stably PEA-15-overexpressing glioma cell lines from U87MG and U251MG cells and selected single clones with expression levels comparable to the primary glioma cell cultures (data not shown). Ectopic expression of PEA-15 resulted in a marked protection from cell death induced by low glucose levels (25 mM) (Figures 3a and b) . However, a Apoptosis in brain tumors A Eckert et al complete lack of glucose in the cell culture medium resulted in the induction of massive cell death after o4 h without significant difference between PEA-15 transfectants and control cells (data not shown). The PEA-15-dependent protection from low glucose-mediated cell death was due to an antiapoptotic effect of PEA-15, since caspase 3 activation by glucose deprivation was inhibited in PEA-15-overexpressing glioma cells (Figure 3c ). Accordingly, transient downregulation of PEA-15 by transfection of specific small interfering RNA (siRNA) oligonucleotides resulted in a sensitization of wild-type glioma cells to caspase 3 activation and low glucose-mediated apoptosis (Figure 3d ), confirming that constitutively expressed PEA-15 contributes to the resistance against glucose deprivation-induced cell death.
Next, we tested whether PEA-15 expression is important for the tumorigenicity of xenografted glioma cells in nude mice. During the early phase of subcutaneous tumor growth and in the absence of a functional neovascularization, the tumor cells are confronted with hypoxia and low glucose levels (Nelson et al., 2004) . To investigate the role of PEA-15 in this model of cellular stress, we downregulated the endogenous PEA-15 expression in U87MG glioma cells by stable infection with a lentiviral PEA-15-specific siRNA construct. The siRNA-PEA-15 and siRNA-control glioma cells were subcutaneously injected into nude mice. Whereas control cells (expressing a scrambled siRNA sequence) formed tumors B2 weeks after glioma cell inoculation, the tumorigenicity of cells with downregulated PEA-15 expression was completely abolished (Figure 3e ). In contrast, the proliferation rates of siRNA-PEA-15 and siRNA-control glioma cells under normal cell culture conditions in vitro were not statistically different (data not shown).
To examine whether the PEA-15-mediated protection from stress-induced cell death was dependent on the phosphorylation status of PEA-15, we treated the glioma cells with CAMKII and PKC inhibitors and performed glucose withdrawal experiments. Importantly, the PEA-15-mediated protective effect was abolished when Ser 116 phosphorylation was inhibited by the CAMKII inhibitor KN-93 or the PKC inhibitor BIS-VIII (Figure 3f ). Furthermore, we generated a nonphosphorylatable PEA-15 variant to examine whether only phosphorylated PEA-15 renders glioma cells resistant to glucose deprivation-induced cell death. We replaced the serine residues at positions 104 and 116 by alanine and generated stably transfected glioma cell lines expressing the PEA-15 S104A/S116A mutant. We found that glioma cells expressing the non-phosphorylatable form of PEA-15 were not protected from low glucoseinduced cell death, although exhibiting comparable expression levels of the PEA-15 transgenes (Figure 3g ). Moreover, we generated a phospho-mimetic PEA-15 variant by replacing the Ser residues at positions 104 and 116 by Glu. Phospho-mimetic PEA-15 mutants were shown to modulate the interaction of PEA-15 with ERK1/2 (Krueger et al., 2005) . The transient expression of PEA-15 S104E/S116E further increased the resistance of glioblastoma cells to glucose deprivation as compared to cells transfected with the wild-type PEA-15 plasmid (Figure 3h ). Equal expression levels of wild-type PEA-15 and PEA-15 S104E/S116E were confirmed by western blot analysis (data not shown). These findings confirm that the antiapoptotic activity of PEA-15 under low glucose conditions depends on its phosphorylation.
PEA-15-mediated resistance depends on ERK1/2 signaling pathways Since there are several reports demonstrating that PEA-15 is involved in MAP kinase signaling, we hypothesized that these pathways may also contribute to the protective effects of PEA-15 observed in our study. In fact, PEA-15 overexpressing glioma cells exhibited constitutively elevated levels of phosphorylated ERK1/ 2 (Figure 4a ). Upon glucose withdrawal, the increase in phosphorylated ERK1/2 was substantially higher in PEA-15-overexpressing cells than in control cells. In contrast, phospho-p38-MAPK levels were unaffected by PEA-15 expression. Accordingly, downregulation of endogenous PEA-15 in wild-type glioma cells resulted in a decrease of phospho-ERK1/2 (Figure 4b ), corroborating that endogenous PEA-15 is involved in the regulation of ERK1/2 phosphorylation. Importantly, treatment of glioma cells with the mitogen-induced extracellular kinase1/2 inhibitor U0126 nullified the protective effect on glucose withdrawal conferred by PEA-15 (Figure 4c ), demonstrating the central role of ERK1/2 signaling for the pro-survival activity of PEA-15. Since ERK1/2 signaling pathways potently promote cellular proliferation, we examined whether PEA-15-overexpressing glioma cells exhibit an altered cell cycle regulation. However, cell cycle distribution was not significantly changed in PEA-15 transfectants and control cells (Figure 4d ). The stable cell clones did not show any signs of aneuploidy (data not shown). Next, we examined the proliferative potency of the PEA-15-expressing glioma cells by performing clonogenicity assays. High PEA-15 expression levels strongly promoted the ability of glioblastoma cells to form colonies (Figure 4e) , suggesting a high proliferative potential of these cells.
PEA-15 upregulates the glucose transporter 3
Since ERK1/2 is a transcriptional regulator of a variety of genes and PEA-15 regulates p-ERK1/2 levels in glioblastoma cells, we wondered whether increased PEA-15 expression would lead to changes in gene transcription of monocarboxylate or glucose transporters. To test whether an increased expression of monocarboxylate transporters renders the PEA-15-overexpressing cells resistant to glucose withdrawal, we blocked the monocarboxylate transporter function with a specific inhibitor, 4-CIN. However, treatment with 4-CIN did not significantly decrease the PEA-15-dependent protection from glucose withdrawal, suggesting that monocarboxylate transporters are not involved in the PEA-15-mediated resistance to low glucose conditions ( Figure 5a ). Next, we examined whether PEA-15 increases the expression of glucose transporters. In fact, upregulation of GLUT3 was detected after transient expression of PEA-15 in U251MG glioblastoma cells (Figure 5b) . In contrast to wild-type PEA-15, the nonphosphorylatable PEA-15 S104A/S116A mutant did not increase GLUT3 expression under low glucose conditions. Similarly, glioblastoma cells with stably siRNA-mediated downregulated PEA-15 did not exhibit an increase of GLUT3 expression after glucose withdrawal (Figure 5c ). Moreover, the glucose withdrawal- abrogates the PEA-15-mediated increase in resistance to glucose withdrawal. Cells were subjected to glucose deprivation (25 mM) for 24 h in the presence or absence of the MEK1/2 inhibitor, U0126 (10 mM). MEK1/2 inhibitor treatment of cells cultured in high glucose did not influence survival rates (not shown). (d) Overexpression of PEA-15 does not alter the cell cycle distribution. Control and PEA-15-transfected U87MG glioma cells were cultured under normal conditions and subjected to cell cycle analysis by flow cytometry. The graph depicts the percentage of cells in the respective cell cycle phases. The differences were not statistically significant (P>0.05, student's t-test, n ¼ 3). (e) PEA-15 promotes the clonogenicity of glioma cells. U251MG cells were seeded in 6 cm dishes (2000 cells/plate) and cultured in a complete DMEM. After 7 days, the dishes were stained with crystal violet and colonies >1 mm were counted. DMEM, Dulbecco's modified Eagle's medium; MEK, mitogen-induced extracellular kinase.
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Discussion
Despite the progress in the diagnosis and therapy of many types of cancer, the prognosis for patients with glioblastomas remains poor. Glioblastoma cells are characterized by a marked cellular resistance against a broad range of cytotoxic stimuli. Interestingly, unlike many other malignant tumors, glioblastomas exhibit numerous intratumoral necrotic areas that develop due to insufficient vascularization, leading to a lack of oxygen and nutrients (Rong et al., 2006 ). An inadequate supply with glucose may be especially deleterious for the glioma cells, since they depend heavily on a high glucose consumption (Ziegler et al., 2001; Elstrom et al., 2004) . In this study, we describe that the PEA-15 protein may play an important role in rendering glioma cells resistant to a lack of glucose, thereby enabling the tumor cells to survive in a poor microenvironment. PEA-15 is known to be involved in glucose metabolism and to contribute to the development of diabetes mellitus. On the other side, there is ample evidence that PEA-15 acts as an antiapoptotic protein, which is involved in MAP kinase signaling as well as other signaling cascades that might be important for the survival of cancer cells. However, the question whether the glucose-related effects of PEA-15 specifically play a role for the cellular resistance of cancer cells has not yet been addressed in detail.
Although PEA-15 was initially identified in astrocytes (Araujo et al., 1993; Danziger et al., 1995) , later reports demonstrated similar expression levels of PEA-15 in neurons and astrocytes (Ricci-Vitiani et al., 2004; Sharif et al., 2004) . Moreover, the expression of PEA-15 has also been reported in mammary gland and keratinocytes as well as in ovarian and breast cancer (Formisano et al., 2005; Krueger et al., 2005; Stassi et al., 2005; Bartholomeusz et al., 2006) . So far, a systematic investigation of PEA-15 expression in astrocytic brain tumors has not been published. Our data demonstrate that the majority 
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116
-phospho-PEA-15 were substantially higher in ex vivo glioblastoma cell cultures than in the two long-term glioma cell lines, U87MG and U251MG. The invasive potential of these two cell lines is significantly lower than that of primary glioblastoma cells; however, U87MG and U251MG cells still exhibit a basal pro-invasive activity that can be demonstrated by in vitro spheroid assays (Del Duca et al., 2004) . Interestingly, the expression pattern of the Ser 116 -phosphorylated form of PEA-15 was most prominent in the perinecrotic areas of glioblastoma. Our observation gave rise to the hypothesis that specific stress factors present in the perinecrotic areas in glioblastomas may induce the phosphorylation of PEA-15.
It has been demonstrated that the phosphorylation status of PEA-15 is crucial for the PEA-15-dependent regulation of apoptosis at the DISC as well as during the MAP kinase-dependent cellular signaling events (Xiao et al., 2002; Krueger et al., 2005) . However, although much is known about these signaling pathways on a subcellular level, it still remains unclear, which physiological (or pathological) conditions induce phosphorylation of PEA-15 in vivo. Our study demonstrates that the PEA-15 protein itself is specifically regulated by phosphorylation upon alterations in extracellular glucose levels. Glucose deprivation-induced phosphorylation of PEA-15 was blocked by inhibitors of CaMKII and PKC. The survival-promoting effect on glioma cells of PEA-15 was dependent on its phosphorylation, since the protective effects were absent after treatment with kinase inhibitors and in a non-phosphorylatable PEA-15 variant. Interestingly, PEA-15 rendered glioma cells resistant to the very stimulus that induced phosphorylation of PEA-15, suggesting the presence of a positive feedback loop. Our results corroborate the hypothesis that phosphorylated PEA-15 acts primarily as an antiapoptotic, pro-survival protein in glioma cells. Our data are also in line with several other reports demonstrating a general pro-survival and tumorigenic role of PEA-15, for example in skin cancer (Dong et al., 2001 ) (Formisano et al., 2005) , breast and ovarian cancer (Bartholomeusz et al., 2006) , and thyroid cancer (Todaro et al., 2006) .
Given the well-characterized binding of PEA-15 to ERK1/2, we wondered whether ERK signaling plays a role in resistance to glucose deprivation in glioblastoma cells. PEA-15 overexpression caused an elevation of p-ERK levels, and siRNA-mediated knockdown of endogenous PEA-15 resulted in the strong downregulation of p-ERK1/2 levels. The loss of glioma cell tumorigenicity upon siRNA-mediated stable downregulation of PEA-15 confirms the crucial role of endogenous PEA-15 expression for the survival of glioblastoma cells in a poor microenvironment, as encountered during the first phase of subcutaneous tumor growth in vivo. Importantly, blockage of ERK1/2 phosphorylation abolished the PEA-15-dependent protection from glucose withdrawal-induced cell death, corroborating that the pro-survival effects of PEA-15 are mediated by ERK1/2 signaling. Our data are in line with the hypothesis that the cellular function of PEA-15 is regulated by its phosphorylation status and depends on ERK1/2; non-phosphorylated PEA-15 tends to block cellular proliferation by inhibiting the nuclear translocation of p-ERK1/2, whereas phosphorylated PEA-15 has lost the ability to bind ERK1/2, followed by the translocation of ERK1/2 to the nucleus and the initiation of antiapoptotic and pro-survival transcriptional signaling. Our study demonstrates that similar regulation mechanisms are present in malignant gliomas. Elevated p-ERK1/2 levels are known to counteract glucose deprivation-induced cell death (Boulos et al., 2007) , which may explain the protective effects of PEA-15 observed in glioblastoma cells. Given the absence of cell cycle-modulating effects of PEA-15, we propose that the PEA-15-dependent and ERK-mediated resistance is rather caused by antiapoptotic (anti-cell death) effects than by ERK-dependent regulation of the cell cycle or proliferation. Our results suggest that the PEA-15-mediated promotion of clonogenicity in vitro and the dependence on PEA-15 of tumorigenicity in vivo are caused by PEA-15-mediated and ERK-dependent antiapoptotic effects in the early phases of these models when the cells are confronted with substantial cellular stress factors due to loss of cell-cell contacts in the clonogenicity assays and hypoxia/nutrient deprivation in the tumorigenicity assay.
The involvement of PEA-15 in the development of diabetes mellitus is well known. Therefore, we were interested whether changes in the expression of glucose transporters would account for the increased resistance of glioma cells against glucose deprivation. The Glucose Transporter 3 (brain-type glucose transporter) is preferentially expressed in brain and neural tissues and was reported to be highly expressed in malignant brain tumors (Nishioka et al., 1992) . Upregulation of the Glucose Transporter 3 upon glucose deprivation was dependent on ERK1/2 phosphorylation, further confirming that the PEA-15-afforded resistance is mediated by ERK1/2 signaling. Our results suggest that PEA-15-induced, p-ERK-dependent upregulation of the Glucose Transporter 3 mediates an increased uptake of glucose under low glucose conditions and thereby contributes to the cellular resistance of glioblastoma cells.
Taken together, our study provides evidence that Ser 116 -phosphorylated PEA-15 promotes the cellular resistance of glioma cells. Therefore, PEA-15 could represent an important resistance factor in glioblastoma, allowing the tumor cells to survive in a poor microenvironment characterized by a lack of nutrients, oxygen and glucose.
Materials and methods

Materials
The following kinase inhibitors were used: KN-93 (Sigma, Deisenhofen, Germany), 1L-6-HMIMO (Calbiochem, Darmstadt, Germany), BIS-VIII (Axxora, Gruenberg, Germany), U0126 (Cell Signaling, Frankfurt a.M., Germany). 4-CIN was purchased from Sigma. The rabbit polyclonal antibody specific for PEA-15 was described before (Sharif et al., 2004) . The antibody to Ser 116 -phosphorylated PEA-15 was obtained from Biosource (Camarillo, CA, USA). The antibody specific for caspase 3 was purchased from Imgenex (San Diego, CA, USA). Antibodies against ERK, p-ERK and p-p38 were obtained from Cell Signaling.
Immunohistochemistry
Ten WHO grade II diffuse astrocytomas, 10 WHO grade III anaplastic astrocytomas and 10 WHO grade IV glioblastomas were analysed for PEA-15 expression by immunohistochemistry. Surgically removed tissue was fixed in buffered 4% formalin (pH 7.4) solution and embedded in paraffin. All surgical glioma specimens were obtained from the Institute of Neuropathology, Bonn University Hospital (Germany). The use of human tissue for study purposes was approved by the local ethics committee at the Bonn University Hospital. Paraffin-embedded tissue sections were de-waxed, treated with citrate puffer (pH 6.0) for 25 min at 991C (Target Retrievel Solution, DAKO, S1699) and incubated for 20 min with blocking solution 1 (1 mg/ml human gglobulin, 20 mg/ml bovine serum albumin in phosphate-buffered saline (PBS)) at room temperature. Next, the blocking solution was removed and the sections were incubated with primary antibody for 60 min at room temperature (PEA-15, 1:4000; S116-phospho-PEA-15, 1:500) or isotype-matched antibodies (rabbit isotype control, Zymed 08-6199, San Francisco, CA, USA). Sections were washed twice in PBS and incubated with blocking solution 2 (20% normal goat serum) for 20 min. After blocking, sections were incubated with secondary biotinylated goat anti-rabbit antibodies (Zymed, for 30 min at room temperature, rinsed twice in PBS for 5 min and incubated with streptavidin-alkaline phosphatase for 30 min (concentrated AP label HK321-UK, BioGenex San Ramon, CA, USA). Next, sections were rinsed twice in PBS, incubated with fast red substrate (Fast Red Substrate System DakoCytomation, Glostrup, Denmark) and counterstained with hematoxylin. For the immunohistochemical semiquantitative assessment of PEA-15 expression, the product of the scores of staining intensity and quantity of immunoreactive tumor cells was calculated based on the following score system: the intensity ranged from 0, negative; 1, low; 2, medium to 3, high; the quantity comprised 0, no expression; 1, positivity in less than 1%; 2, positivity in 1-9%; 3, positivity in 10-50% and 4, positivity in more than 50%. Immunoreactivity of normal brain tissue was assessed in the vicinity of tumor tissue of patients with diffuse astrocytomas.
Cell culture and viability assays
The human glioma cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 1 mM glutamine and 1% penicillin/streptomycin. For the preparation of primary (ex vivo) glioma cell cultures, human brain tumors were obtained from patients with glioblastomas who underwent surgery for tumor resection (Department of Neurosurgery, University of Heidelberg). The short-term tumor cultures were established as described (Karcher et al., 2006) . The percentage of surviving cells was assessed either by counting cells directly after trypsination and staining with trypan blue or by staining with crystal violet (Gillies et al., 1986) . For the glucose deprivation experiments, a DMEM containing 25 mM glucose was removed and after two washes with PBS, it was replaced by a DMEM containing 25 mM glucose, unless indicated otherwise. For clonogenicity assays, 2000 glioma cells were seeded in 6 cm dishes and incubated in a complete DMEM for 7 days. After staining with crystal violet, cell colonies >1 mm in diameter were counted. For experiments under hypoxic conditions, cells were incubated in a hypoxic chamber for 16 h in the presence of oxygenbinding catalysts.
Site-directed mutagenesis of PEA-15 To substitute both phosphorylation sites (Ser104 and Ser
116
) of PEA-15 by alanine, pcDNA3-PEA15 was used as a template in two successive rounds of mutagenesis using the QuickChange site-directed mutagenesis method (Stratagene, Amsterdam, The Netherlands). To substitute Ser104 by an Ala, the primer 5 0 -AACCCGTATTCCCGCTGCCAAGAAGTACA-3 0 and its reverse complement were used. To exchange Ser 116 for Ala, pcDNA3-PEA-15 S104A served as template using the primer 5 0 -ATTCCGGCAGCCCGCTGAAGAAGAAATCA-3 0 and its reverse complement. For each step, 13 cycles were performed. For the generation of the phospho-mimetic mutant pcDNA3-PEA-15 S104E/S116E , the non-phosphorylatable double-mutant pcDNA3-PEA-15 S104A/S116A served as a template in two successive PCR rounds. To substitute Ala104 by a Glu the primer 5 0 -AACCCGTATTCCCGAAGCCAAGAAGTA CA-3 0 and its reverse complement were used. To exchange Ala116 by Glu, pcDNA3-PEA-15 S104E/S116A served as a template using the primer 5 0 -ATTCCGGCAGCCCGAA GAAGAAGAAATCA-3 0 and its reverse complement. The presence of the desired mutations was confirmed by DNA sequencing.
FACS analysis
The analysis of the cell cycle distribution of glioma cells was performed using a fluorescence-activated cell sorting (FACS)-calibur (Becton Dickinson, Heidelberg, Germany) equipped with a 488 nm air-cooled argon laser with filter combinations for propidium iodide. For histogram and plot analysis, the Cell Quest software (Becton Dickinson) was used. The ModFit software program (Verity Software House Inc., Topsham, ME, USA) was used for cell cycle analysis.
Transfections U87MG and U251MG human glioblastoma cells were stably transfected with pcDNA3 neo (control), pcDNA3-Flag-PEA-15 (Danziger et al., 1995) or pcDNA3-Flag-PEA-15 S104A/S116A plasmids using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany). For transient transfections, HeLa cells were transfected using Lipofectamine 2000 (Invitrogen) with plasmid DNA encoding Flag-PEA-15, Flag-PEA-15 S104A/S116A or an empty vector control, pcDNA3 neo. For the knockdown of endogenous PEA-15, glioma cells were transiently transfected with 50 nM siRNA (Ambion, Austin, TX, USA) by lipofection in the presence of Lipofectamine 2000. The following sequence was chosen to specifically target PEA-15: 5 0 -GCGAAAAGA GUGAGGAGAU-3 0 (sense); 5 0 -AUCUCCUCACUCUUUU CGC-3 0 (antisense).
Immunoblot analysis
Immunoblot analysis was performed as outlined in Supplementary Information 1.
Two-dimensional gel electrophoresis
For analysis of the phosphorylation status of PEA-15, stably PEA-15-transfected U87MG cells were incubated for 6 h under low-glucose conditions. PEA-15 was enriched by immunoprecipitation with M2-Flag beads (Sigma). Beads were eluted in 150 ml 2-D-sample buffer (2-D Sample Prep Kit, Pierce, Rockford, IL, USA) for 30 min at 301C. After centrifugation, the supernatants were collected and were loaded onto immobilized dry strips, pH 3-5,6 (11 cm, GE-Healthcare, Uppsala, Sweden). Isoelectric focussing was carried out as follows: 300 V for 30 min; 1000 V (gradient) for 30 min; 5000 V (Gradient) for 1.5 h; 5000 V for 1.5 h. The gels were incubated twice for 12 min in equilibration buffer (6 M Urea, 50 mM TrisHCl, pH 8.8, 30% glycerol, 2% sodium dodecyl sulfate, 1% dithiothreitol). The second dimension was applied on 4-12% polyacrylamide gels (NuPAGE). After semidry blotting, phosphorylated and total PEA-15 were detected with antiphospho(Ser Quantitative PCR analysis Quantitative PCR analysis was performed as outlined in Supplementary Information 2.
Generation of stably siRNA-infected glioma cell lines To target the PEA-15 protein for downregulation by siRNA, we generated the pSUPER-PEA-15 construct and, as a control, pSUPER-siRNA-control according to the manufacturer's instruction (OligoEngine, Seattle, WA, USA). For primer sequences, see Supplementary Information 3. The siRNA sequence including the H1 promotor was subcloned into the lentiviral expression vector pG-Lenti (kindly provided by Carol Stocking-Harbers, Hamburg, Germany), which expresses GFP under the control of the SFFV promoter. Amphotropic retroviral supernatants were produced by transient transfection of 293T cells with the retroviral packaging vectors pMDLg/pRRE, pRSV-Rev and pMD.G and the corresponding siRNA construct. U87MG and U251MG cells were infected at least two times with retroviral supernatant. Positive clones were selected by GFP expression and verified by western blot analysis.
Animal studies All animal work was carried out in accordance with the NIH guidelines 'Guide for the Care and Use of Laboratory Animals'. U87MG glioma cells (7.5 Â 10 6 ) were subcutaneously injected into the flanks of 6-week-old male athymic CD1-nude mice (Charles River, Sulzfeld, Germany) using a 30-gauge needle. Tumor volume was measured at least three times per week using a caliper. The tumor volume was calculated using the following formula: (long axis Â short axis 2 )/2.
